Altay Therapeutics
CompanyUnited States
Altay Therapeutics develops 3 assets, the furthest preclinical (DX5057 in facioscapulohumeral muscular dystrophy). Mostly small molecule acting on DUX4 and STAT3; based in the United States.
- 3
- Assets
- Furthest stage
- Preclinical
- Raised
- US$52.7m
- 1
- Grant
- 0
- Trials
- 2
- Signals
Pipeline
3Oral small molecule inhibition of DUX4, the transcription factor driving FSHD pathology.
Preclinical, Small molecule, DUX4, facioscapulohumeral muscular dystrophy
Binds directly to activated STAT3 to inhibit its activity.
Preclinical, Small molecule, STAT3, cancer, inflammatory diseases
Undisclosed Program in Oncology
Inhibits an undisclosed transcription factor.
Preclinical, Small molecule, prostate cancer, sarcomas
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Funding rounds and grants2
- People23
- Signals2
- Similar companies6